An ulcerative colitis trial can look promising on a feasibility questionnaire: experienced investigators, an established gastroenterology referral base and patients living with inflammatory bowel disease. Yet the enrollment forecast can fall apart when the site has to confirm current disease activity, document treatment history, arrange a protocol-specific endoscopy and keep the participant engaged through follow-up.
For sponsors and CROs, selecting a UC clinical trial site should mean evaluating two linked capabilities: access to the right people and an executable path through the required assessments. A large patient list cannot compensate for unreliable procedure access, and a well-equipped procedure partner cannot create eligible patients.
Start with the trial population, not the diagnosis count
Ulcerative colitis is not a single operationally uniform population. A patient may have a documented diagnosis but be in remission, receiving an excluded therapy, taking a prohibited medication, or unable to satisfy the protocol's required disease activity thresholds. Some studies require prior exposure to specific advanced treatments; others have different treatment-history restrictions. The latest protocol, not an indication-level estimate, defines the pool.
Ask the site to describe how it will distinguish an EMR diagnosis from a prescreened potential candidate. Relevant records can help identify referrals and treatment histories, but a coordinator and investigator still need to verify dates, medications, prior response, availability and consent to be contacted through approved procedures.
The strongest estimate acknowledges what cannot be confirmed before a proper screening visit. Instead of an attractive headline count, sponsors should request an evidence-based funnel: records reviewed, likely matches, reachable individuals, likely consenters, projected screen failures and expected randomizations. WCR's gastroenterology research overview describes the protocol-led review of patient access, investigator fit and local procedure requirements.
Map the endoscopy pathway before startup
Endoscopic assessment can be central to UC diagnosis and research. The National Institute of Diabetes and Digestive and Kidney Diseases describes colonoscopy and flexible sigmoidoscopy, often with biopsies, as ways clinicians assess the extent and severity of ulcerative colitis. Whether a particular study requires one or both, who interprets images and how specimens are handled depends on its protocol.
The FDA's April 2022 draft guidance on developing drugs for UC discusses clinical trial populations, efficacy assessment and patient-reported symptoms alongside endoscopic measures. It is draft, nonbinding guidance, not a universal recipe for every UC protocol. Sponsors should translate their actual assessment schedule and central-reading instructions into a site-specific procedure plan.
Confirm who will perform the procedure, where it will occur, what the booking lead time looks like, who documents bowel preparation, and how the endoscopy images reach any required central reviewer. Ask what happens if the participant has a poor preparation, an appointment is canceled or the image transfer fails. A vague answer such as "we have GI access" is not operational readiness.
Decide ownership across the entire specimen and data chain
If the protocol requires mucosal biopsies, central pathology, stool testing or serial blood samples, the research team must map every handoff. The physician performing the procedure, the research coordinator, the lab, the courier and the sponsor's central vendor may all have different responsibilities. Confirm collection supplies, timing, labeling, processing, temperature conditions, pickup windows and reconciliation of missing or rejected samples.
Endoscopy reports and source records also need to be traceable to the correct visit and the protocol-required interpretation. A site should explain when the investigator reviews results, how a repeat assessment is handled, and how unresolved queries are escalated. The practical question is not whether every service is physically on site, but whether required services have a qualified, dependable pathway.
A useful walkthrough follows one hypothetical participant from scheduling to results receipt. Ask each team member to state what they own and what evidence confirms completion. This often reveals fragile dependencies before the first screening appointment.
Understand investigator experience and referral relationships
An investigator's GI trial experience matters, but sponsors should look beyond a general specialty label. Ask about experience with UC activity scales, treatment history review, eligibility adjudication and managing symptoms or safety concerns between scheduled visits. Then identify which people will actually conduct each assessment and who covers the study when the lead investigator is away.
WCR's public investigator roster includes gastroenterology and inflammatory bowel disease experience in its Miami Lakes and Vega Baja network. WCR has also documented publications involving investigators Lucky Flores and Gustavo Albizu-Angulo in ulcerative colitis research. These are useful evidence of research involvement; they are not proof that every investigator or procedure will be available for a future sponsor protocol.
For each proposed location, verify the named investigator, delegated staff, referral partners and any external endoscopy arrangements against the study's requirements. Sponsor teams should ask for the actual coverage plan rather than assume that a network-level capability exists at both sites in the same form.
Make the visit schedule workable for participants
UC participants may face urgent symptoms, variable disease activity, work and family obligations, bowel preparation and additional visits for laboratory or endoscopic assessments. An enrollment plan that ignores these demands can overstate both recruitment and retention. Sponsors should ask how the site explains visits, gives preparation instructions, manages rescheduling and promptly responds to participant questions.
Participant communication should be in the language the individual understands, using approved materials and the consent process required for the study. Recruitment and retention planning should cover more than first contact: visit reminders, symptom escalation, procedure travel, diary support and follow-up after missed appointments.
It is reasonable to ask the site to model a real participant's likely number of trips and waiting periods. The resulting burden may suggest scheduling changes, different visit windows where allowed, or better explanation of the time commitment before consent. Nothing in this process should be presented as a guarantee of benefit or eligibility.
Use a practical sponsor and CRO readiness check
A feasibility meeting is most productive when the team leaves with a named owner and evidence for each critical dependency. The following questions can be answered during site selection and revisited at site initiation.
- Population: Which inclusion and exclusion rules can be prescreened from records, and which require direct study assessments?
- Competing studies: Are active GI protocols likely to draw on the same referral and treatment-history population?
- Procedures: Which endoscopist, location, equipment and appointment windows are available for the protocol?
- Images and specimens: Who handles central reading, biopsies, sample preparation, shipping and data queries?
- Oversight: Which investigator and staff roles are delegated, trained and covered during absences?
- Participant pathway: How will preparation, bilingual communication, travel and unplanned follow-up be coordinated?
- Forecast: What assumptions support expected screening and randomization within the actual enrollment window?
How WCR approaches UC protocol discussions
Wellness Clinical Research operates a coordinated research network in Miami Lakes, Florida, and Vega Baja, Puerto Rico. Its public capabilities describe multi-specialty investigator review, established patient relationships, sample processing and coordinated local endoscopy access. "Coordinated access" is deliberate wording: it does not mean that every endoscopy service, reader or specialty procedure is performed inside both WCR locations.
For a new UC study, the appropriate conversation begins with the full schedule of activities, medication and prior-therapy requirements, required assessments and the proposed site location. The team can then evaluate investigator fit, the patient-identification pathway, procedure partners, specimen workflow and participant support. Feasibility should remain conditional until those details are verified.
Sponsors and CROs evaluating a specific study can submit a protocol for review. The objective is a transparent yes, no or conditional feasibility response with clear responsibilities, rather than a promise based on diagnosis counts alone.
